Some items on our site have recently moved. Visit our News Hub for selected articles, special reports, podcasts and other resources.
AbbVie, Allergan well-positioned for unconditional clearance in Brazil
22 October 2019 12:41 by Ana Paula Candil
AbbVie’s $63 million merger with Allergan is well-positioned for unconditional antitrust clearance in Brazil, MLex has learned.
Approval by the Administrative Council for Economic Defense, or CADE, is expected to be announced soon.
AbbVie and Allergan submitted merger paperwork on Aug. 22, but amended their notification form, pushing the review deadline to Nov. 14.
AbbVie and Allergan are listed on the New York Stock Exchange.
Related Articles
-
Chipmaker Broadcom plans a $61 billion buyout of cloud giant VMware might give observers a feeling of déjà vu -
US DOJ’s Kanter has been criticized within the antitrust bar for saying it isn’t the government's job to help companies fix illegal mergers -
UK prohibition of a Big Tech deal will be tested in court as Meta Platforms fights to get an order requiring it to unwind its purchase of Giphy quashed